Harmony Biosciences (NASDAQ: HRMY) reported Q3 EPS of $1.08, $0.34 better than the analyst estimate of $0.74. Revenue for the quarter came in at $239.5 million versus the consensus estimate of $220.04 million.

GUIDANCE:

Harmony Biosciences sees FY2025 revenue of $845-865 million, versus the consensus of $860.5 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.